1-9 of 9
Shahabuddin Usmani
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Differentiation Scoring (DS) Derived from Cellworks Computational Omics Biology Model (CBM) Predicts Response to Hypomethylating Agents (HMA) and Patient Survival in Myelodysplastic Syndrome (MDS)

Michael Castro, Shahabuddin Usmani, Ansu Kumar, Jyoti Chauhan, Shweta Kapoor, Swati Khandelwal, Vivek Patil, Subrat Mohapatra, Anuj Tyagi, Mohammed Sauban, Prashant Ramachandran Nair, Vijayashree P. Shyamasundar, Neha Dutta, Upasana Mitra, Neha Gupta, Nagendra Prasad, Ashish Kumar Agrawal, Ashokraja Balla, Rakhi Purushothaman Suseela, Veena Balakrishnan, Kishore Promod, Sanjana Patel, Michele Dundas Macpherson, James Wingrove, Scott C. Howard, Guido Marcucci
Journal: Blood
Blood (2022) 140 (Supplement 1): 4970–4971.
https://doi.org/10.1182/blood-2022-166284
Published: 2022
Journal Articles

Predictive Analysis on Prognostic Impact of Monosomy 7 in AML and Identified Therapy Options for This Cohort

Shireen Vali, PhD, Christopher R. Cogle, MD, Neeraj Arora, MD, Krishnan Shekhar, PhD, Mammen Chandy, MD, Manju Sengar, MD DM, Hasmukh Jain, MD DM, Girish Chinnaswamy, MD MRCP, Neeraj Kumar Singh, B.Tech, Shahabuddin Usmani, M.Sc., Anusha Pampana, M.Sc., Vijayashree P Shyamasundar, M.Sc., Huzaifa Sikora, B.Tech, Ansu Kumar, M.Sc., Taher Abbasi, MS, MBA, Vivek S Radhakrishnan, MDDM,MSc
Journal: Blood
Blood (2018) 132 (Supplement 1): 1539.
https://doi.org/10.1182/blood-2018-99-116603
Published: 2018
Journal Articles

Analysis of the Evolving MDS/AML Clones to Identify Resistance Mechanisms and Predict New Therapy Options at Relapse Using Computational Biology Modeling: Case-Studies from iCare1 Clinical Study

Shireen Vali, PhD, Taher Abbasi, MS, MBA, Neeraj Kumar Singh, B.Tech, Shahabuddin Usmani, M.Sc., Deepak Anil Lala, B.Tech, Poornachandra G, B.Tech, Saumya Radhakrishnan, B.Tech, Shivgonda C Birajdar, MCA, Ganesh Naga, B.Tech, Leylah M. Drusbosky, PhD, Christopher R. Cogle, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3086.
https://doi.org/10.1182/blood-2018-99-115821
Published: 2018
Journal Articles

Digital Drug Screening and Computational Modeling Identifies Treatment Opportunities Despite Lack of Directly Actionable Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Leylah M. Drusbosky, PhD, Kimberly E. Hawkins, PhD BS, Madeleine Turcotte, MS, Hemant S. Murthy, MD, Helen L. Leather, Nosha Farhadfar, MD, Maxim Norkin, MD, John R. Wingard, MD, John W. Hiemenz, MD, Paul Castillo, MD, Randy A. Brown, MD, William Slayton, MD, Biljana N. Horn, MD, Sumanth Vasista, BE, Kabya Basu, MS, Shahabuddin Usmani, MS, Kunal Ghosh Roy, MS, Deepak Anil Lala, BT, Saumya Radhakrishnan, BT, Rajeev Kumar, BT, Swaminathan Rajagopalan, MT, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Christopher R. Cogle, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3910.
https://doi.org/10.1182/blood.V130.Suppl_1.3910.3910
Published: 2017
Journal Articles

Predictive Simulation Modeling in JAK2-Mutant MPNs Identified Ruxolitinib and Sorafenib As a Synergistic Drug Combination for Disease Modifying Therapy

Peter P. Sayeski, PhD, Leylah M. Drusbosky, PhD, Neeraj Kumar Singh, B.Tech, Anusha Pampana, Shahabuddin Usmani, MS, Mohammed Sauban, BE, Abha Kushwaha, Anu Ramakrishnan, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Christopher R. Cogle, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5287.
https://doi.org/10.1182/blood.V130.Suppl_1.5287.5287
Published: 2017
Journal Articles

A Genomic Signature Predicting Venetoclax Treatment Response in AML Identified By Protein Network Mapping and Validated By Ex Vivo Drug Sensitivity Testing: A Beat AML Project Study

Leylah Drusbosky, PhD, Taher Abbasi, Shireen Vali, PhD, Saumya Radhakrishnan, Neeraj Kumar Singh, Shahabuddin Usmani, Deepak Parashar, Robinson Vidva, Brian J. Druker, MD, Cristina E. Tognon, Pierrette Lo, MS, Jeffrey W. Tyner, Christopher R. Cogle, MD
Journal: Blood
Blood (2016) 128 (22): 1713.
https://doi.org/10.1182/blood.V128.22.1713.1713
Published: 2016
Journal Articles

Computational Analysis of Genomic Abnormalities from a Phase 3 Trial of Rigosertib in Higher-Risk MDS: Simulation of a Predictive Signature for Clinical Response

Guillermo Garcia-Manero, MD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Bernard Brownstein, MD, Hannes Loferer, PhD, Nozar Azarnia, PhD, Shireen Vali, PhD, Neeraj Kumar Singh, Shahabuddin Usmani, Himanshu Grover, Taher Abbasi, Lewis R. Silverman, MD
Journal: Blood
Blood (2016) 128 (22): 4324.
https://doi.org/10.1182/blood.V128.22.4324.4324
Published: 2016
Journal Articles

A Genomic Predictive Signature for Rigosertib in Lower Risk MDS Derived By Integrating Clinical Response, Mechanism of Action Data and Simulation

Steven M. Fruchtman, MD, Abdullah Mahmood Ali, PhD, Michael E. Petrone, MD MPH, Patrick Simon Zbyszewski, MBA, Benjamin Hoffman, PhD, Shireen Vali, PhD, Neeraj Kumar Singh, Shahabuddin Usmani, Himanshu Grover, Taher Abbasi, Azra Raza, MD
Journal: Blood
Blood (2016) 128 (22): 5535.
https://doi.org/10.1182/blood.V128.22.5535.5535
Published: 2016
Journal Articles

In Silico Modeling of Oncogenic Drivers in Waldenstrom Macroglobulinemia to Assess Additional Therapeutic Targets within the BCR Signaling Pathway Identifies MEK1/2 As a Target: Potential Therapeutic Role of Binimetinib

Aneel Paulus, MDMS, Sharoon Akhtar, MPhil, Shireen Vali, Ansu Kumar, Neeraj Kumar Singh, Shahabuddin Usmani, Himanshu Grover, Taher Abbasi, Asher Alban Chanan-Khan, MD
Journal: Blood
Blood (2015) 126 (23): 1279.
https://doi.org/10.1182/blood.V126.23.1279.1279
Published: 2015